We use cookies to improve your experience on this site. By viewing our pages, you give us consent to use cookies. Find out more.

Don’t invest unless you’re prepared to lose all the money you invest. NextFin promotes high - risk investments and you are unlikely to be protected if something goes wrong.
Take 2 minutes to learn more.

Equity Crowdfunding Pitches

Showing results
Wi-Fi Securities Limited is a cyber security company that aims to revolutionise the security of public access Wi-Fi. To realise this vision, the company is developing a unique patent-protected system called SpriteGuard™ which will protect you and your data from hackers by stopping you connecting to fake hotspots. The system is targeted towards the $550 bn worldwide hospitality industry and has the ability to expand to other large global markets like city-wide free Wi-Fi, airports and coffee shops. Moreover, Wi-Fi Securities Limited has a highly experienced Wi-Fi Securities management board that has a track record of delivering multi-million-pound projects from concept to successful commercial deployment.

Pitch Rated

77%

Overall

rating powered by

CROWD RATING™

days to go: Extended investment: £1,014,708
Carocell Bio is innovating by developing patented anti-inflammatory peptides delivered via nanoparticles to address severe inflammatory conditions such as atopic dermatitis. Their primary peptide, JEL0305, not only halts inflammation but also prevents its initiation, as evidenced by its effectiveness in reducing inflammation in human AD biopsies and burn tissue. With AD impacting a substantial population and costing $21 billion yearly for unsafe treatments, Carocell Bio's safer peptide remedy has the potential to avert AD recurrence. Additionally, their pioneering approach to skin-related inflammation involves topical peptide products that target mitogen-activated protein kinase (MAPK), a crucial element in inflammation. This breakthrough offers promise for managing and forestalling AD and mitigating skin aging.
days to go: Extended investment: Withheld
Doqit offers a solution for managing life admin tasks, helping you organize important information, set action dates, and receive timely reminders, ultimately streamlining tasks like insurance renewals and warranties to reduce unnecessary expenses and simplify your life. It provides secure storage and easy access for vital information, transitioning from chaos to simplicity.  Security is also a priority for Doqit. The platform ensures that your sensitive information is stored securely, giving you peace of mind knowing that you can access your important documents and data whenever you need them, all within a few clicks.
days to go: Extended investment: £87,500
Morgan Goodwin is a UK-based company that pioneers the Combined Trading Platform (CTP) category, offering a comprehensive online platform for small businesses engaged in physical goods trading, along with specialized software development services, and a broad-spectrum business consultancy approach aimed at enhancing growth, efficiency, and technological advancement.
days to go: Stretch investment: £788,519
Optimise BP, the debut product by Optimise Health, introduces an innovative digital solution that offers secure and efficient semi-automated blood pressure management within primary care, focusing on hypertension. This advancement is projected to lead to substantial appointment savings in the range of millions.
days to go: TBC investment: £127,001
PULMOBIOMED is addressing the failings of current lung tests, which are expensive, infrequent, and invasive. Their so-called "clinically proven" solution claims to offer non-invasive liquid samples from deep within the lung, promising affordable tests for lung diseases. They assert that their product can empower clinicians to diagnose and treat conditions like lung cancer and infections, even though there's limited evidence to support these claims. With a few customers in the USA and Australia, and vague partnerships in the EU, PULMOBIOMED hopes to disrupt the asthma diagnostics market by introducing what they call a comprehensive diagnostic test for asthma, despite the skepticism around their capabilities.
days to go: Extended investment: £295,000
UTU is a company dedicated to building the trust infrastructure for the evolving web 3.0. They aim to facilitate safer and more reliable interactions between users and platforms by utilizing a decentralized reputation and reviews protocol. This protocol involves a non-tradable reputation token (UTT) that users can stake to endorse others, leading to positive outcomes. UTU's focus initially lies in Web3 and DeFi apps, where they provide AI-powered tools to curate trust signals and help users engage confidently in various online activities. They offer a range of products, including the UTU Trust Token, Browser Extension, and Trust API/SDK, all aimed at enhancing trust and security in digital interactions.
days to go: Extended investment: £150,000
Football Fan (FF) aims to become the go-to app for anything Football. FF asserts that Football (Soccer) is a dynamic all year sport with 4+ billion football fans generating business opportunities like merchandising, advertising, ticketing, gaming, travel, streaming, and more. FF believes that these fan bases are diluted on many platforms to meet their daily Football needs. FF aspires to change this by offering a blend of SportsTech with business opportunities supported by fan-engagement features on its app. Fans can connect with other fans or their club, create stories, watch videos, follow live scores, in-game events and statistics, post opinions/reactions, use banter rooms, and more. The app also rewards fans with FanCoins based on their contribution. FF app has witnessed over 22,000 downloads with 1.5 million+ interactions since its launch in June 2020. The company will use the investment to fuel user growth, starting with an initial focus on English Football and its fandom.

Pitch Rated

85%

Gold

rating powered by

CROWD RATING™

days to go: Expired investment: £320,853
miiCARE is a MedTech specialising in AI applied to geriatrics (elderly care). Its key product miiCUBE offers cutting-edge home-based and customised healthcare, helping the elderly enjoy their independence while being comprehensively connected to their families, friends, and neighbours. The company aims to provide these benefits to one billion people by 2028, comprising older people, family members and carers. Till date, miiCARE has secured partnerships with the UK’s largest NHS trust, Ebbsfleet Garden City, O2, Bristol Careline and Microsoft, and won multiple social impacts and digital health awards during the last 12 months. Funds raised will be used mainly for fulfilling pre-orders and close interests for large contracts with corporates, marketing and logistics, product development, sales and salaries.

Pitch Rated

84%

Gold

rating powered by

CROWD RATING™

days to go: Expired investment: £103,672
Blind Cupid (BC) is a disruptive personal matchmaker that uses systematic philosophy and Artificial Intelligence (AI) to help users find their long-term partners with the very first match. It does this by asking its users high-quality, short, and introspective questions that reveal what the company calls a user's ‘Sense of life’. The AI system then comes up with potential matches by analysing the above data along with the user's communication style. BC asserts that the global matchmaking market has 91 million users and is currently worth £4.65 billion (2020) with a projected value of £7.68 billion by 2026. It argues that 4 out of 5 beta users met their potential partner on its portal. The company aims to patent its AI and licence it out to eager organisations. It will use the investment to offer investors the opportunity to be a part of the next generation of matchmaking and artificial intelligence.

Pitch Rated

82%

Gold

rating powered by

CROWD RATING™

days to go: Expired investment: £354,989
  • Internet Business Awards Category Award Winner 2015
  • Hertfordshire Business Awards Finalist 2014

As seen in:

  • The Guardian
  • Financial Times
  • Yahoo! Finance
  • The Times
  • The Daily Telegraph